Renalytix Share Discussion Threads

[mr roper] 02/12/2022 14:20

Easier product to fund if its got a moat and you can show increasing sales. Which they are doing.

To expand and grow that's where they'll need help either by raising themselves or a partner with an embedded sales network.

Expecting news on that at end of q1 with hopefully fda approval in the bag

[columbarius] 02/12/2022 13:13

'Puts a moat around the product'

Also the mind boggling amount of money you need to put in to get started in the US health market. The rewards are there but you need a good product and sales team and very deep pockets.

[homebrewruss] 02/12/2022 11:51

Chart is looking much better! :)

[theonewhoknows2] 02/12/2022 10:15

brought back in today gla

[mr roper] 01/12/2022 09:04

I think this is one of the key points

"And these data results take years to put together"

Puts a moat around the product

[wan] 01/12/2022 08:25

To add to that thought process, transcript excerpt from yesterdays webcast -

James McCullough

I think it's important to note again that there is a large intrinsic value, which has been accumulating through the real world evidence program. The data results just published, as Tom mentioned, showing benefit within six months. We believe is exceptional and quite novel in the space. And these data results take years to put together. They're very expensive. But once they're in place, they now begin to continue to accumulate.

So, the real world evidence program is not only very strong, but it's growing and it will continue really on an every six month basis to put up new and additional longitudinal data to support use of KidneyIntelX [to] [ph] primary care. And this, as Tom mentioned, goes directly to generating coverage determinations, percentage of coverage, etcetera. So, we're really, I believe, with insurance payment, we're very much at an accelerating point.

In 2023, we'll continue to see regions, including large population center regions, developing comprehensive coverage across large populations.

[wan] 01/12/2022 08:18

Edit to the above post, added the link and commentary excerpt.

[wan] 01/12/2022 08:02

Plus, we have some important highlights announced today from the clinical utility study, further underscoring my comment that the growing body of real-world utility evidence has reached a tipping point, which importantly will grow as the study continues -

According to Michael J. Donovan, PhD, MD, Chief Medical Officer at Renalytix, "The impacts of KidneyIntelX early risk assessment, at 90 days and 180 days, are very encouraging as we can now state that we have observed early intervention in the highest risk patients can result in positive clinical outcomes, before kidney disease advances to a critical point. This prospective study in a real-world health care system setting demonstrates that risk informed care in the earliest stages of chronic kidney disease is not just a vision, it's a reality. Until the introduction of KidneyIntelX testing, there has not been a good way to allocate time and attention in the PCP practice to those patients at highest risk for progression to end stage renal disease. This published data shows that KidneyIntelX can help to drive urgency to action and increase patient engagement in the management of their disease."

"These groundbreaking results demonstrate that we have the opportunity to make a tangible difference today in two of the most complex chronic disease conditions that the U.S. faces today: type 2 diabetes and chronic kidney disease. These results represent a triple win - they're good for the patient, they're good for the provider, they're good for the payer. We look forward to continuing to advance our clinical development program and to additional published data releases at the one-year mark," added Thomas McLain, President, Renalytix.


Put another way, the case for adoption of KidneyIntelX is going to get evermore compelling.

[wan] 01/12/2022 08:01

Courtesy of Ramyris on Discord in the US -

Stifel Research

Buy - price target $6

"we note that the next 4-6 months could/should contain multiple catalytic events"

[wan] 30/11/2022 09:35

Reminder: live conference call webcast at 1:30 UK time -

Renalytix First Quarter Fiscal Year 2023 Earnings Call and Webcast
November 30, 2022 at 8:30 AM EST

[wan] 30/11/2022 08:09

As expected not much to add from that guided in the recent Full Year Results.

I note another increase in the private insurance and network provider contracts to 30.

VA medical system is live and progressing and remains one to watch in my view, with the potential to add materially to testing volumes.

[mr roper] 30/11/2022 07:55

Yes I have sold a fair chunk but still interested in the company.

[faz] 29/11/2022 22:22

I remember you posting when the share hit $35 overnight in the US. I ws only 22 months ago. Have you not sold one share in all that time. I monitor the company, because I want to understand the cycle of hype , price and performance. No criticism is intended.

[mr roper] 29/11/2022 21:20

+25% Stateside finish.

[mr roper] 29/11/2022 15:56

Very Nice looking bowl on the chart

[homebrewruss] 29/11/2022 15:34

News seems to have been well received stateside

[mr roper] 29/11/2022 10:26

Expecting an Illinios health care system announcement shortly

[wan] 29/11/2022 10:09

Hashertu...Personally speaking, I think that the growing body of real-world utility evidence has reached a tipping point in both regards. Plus, the increasing number of listed Commercial Health Plans covering KidneyIntelX, not to mention the VA contract and the current coverage of testing for patients with Medicare coverage, all add further weight. If I am right, further adoption by care systems/health plans is likely to be more a case of when and not if.

FDA authorisation, not required for coverage/adoption, will of course also help, but perhaps in particular with regard to a strategic partner, which may also assist matters in terms of adoption.

[hashertu] 29/11/2022 09:34

Wan, I agree that it is encouraging.
Do you know how long it takes (or will take)a care system to determine that this analysis leads to better patient health and reduced costs?

[wan] 29/11/2022 07:47

Very encouraging Interim Results on Decision Impact and Outcomes this morning. The increase in new drug prescriptions (for SGLT2 inhibitors) will no doubt also be duly noted by pharma.

Plus, it can not be anything less than supportive of Renalytix FDA De Novo marketing authorization for KidneyIntelX.

Full study publication -

[wan] 22/11/2022 08:21

The following is also thought provoking -

Walgreens plots 'aggressive' strategy to build out healthcare services, CEO Roz Brewer says
By Heather LandiNov 21, 2022

On the heels of several high-profile acquisitions, Walgreens aims to be a point of entry for consumers for healthcare services ranging from urgent care to specialty care and even in-home health.

Walgreen's VillageMD unit recently announced it was buying another urgent and primary care chain, Summit Health-CityMD, in a deal worth close to $9 billion. The VillageMD-Summit Health deal will expand Walgreen's reach into primary, specialty and urgent care. Combined, VillageMD and Summit Health will operate more than 680 provider locations in 26 markets.

Walgreens Boots Alliance and VillageMD have 52 co-located primary care practice locations currently open and will have more than 80 open by the end of this calendar year. Last year, Walgreens invested $5.2 billion in VillageMD, becoming the majority owner, and said it planned to open at least 600 Village Medical at Walgreens primary care practices across the country by 2025 and 1,000 by 2027.

"When you think about the full healthcare landscape, there are partnerships absolutely to be had. I don’t want to invest in and buy everything," she said, adding, "we’re not a tech company, but we’re going to depend on technology so I could see us having a really strong technical partnership at some point."

Full article -

Nephrologists at Summit Health are experts in diagnosing and treating kidney disease and hypertension. Summit Health provides hemodialysis and peritoneal dialysis. When it is necessary, our physicians refer patients for kidney transplantation.

Some conditions that can cause kidney failure include hypertension, diabetes, polycystic kidney disease, and glomerulonephritis.

Because of the complex role of the kidneys in your overall health, we recommend that you consult your primary physician (internist or pediatrician) if you are experiencing health problems or have a condition that might affect your kidneys.

Conditions Requiring a Nephrologist
Our nephrologists diagnose and treat:
Acute and chronic renal failure
Blood or protein in the urine
Chronic kidney disease
Kidney function that declines over time
Electrolyte imbalances
Kidney stones
High blood pressure (hypertension)

[wan] 22/11/2022 08:11

KidneyIntelX platform is designed to scale across kidney disease conditions beyond diabetic kidney disease. Renalytix are evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. They’re also continuing with next generation work on their current diabetic kidney disease indication while they explore ways to expand access to patients around the world.

Renalytix next generation work and their out-of-the-gate focus on Diabetic Kidney Disease, continues to provide food for thought in terms of strategic partnerships, especially given the likes of Bayer's recent news -

New Clinical Guidelines Recommend Finerenone for CKD Associated With T2D
November 21, 2022

“Kerendia’s inclusion in the KDIGO guideline update and ADA and KDIGO consensus report reinforces its foundational and critical role in a multipillar treatment strategy for patients with CKD associated with T2D who seek cardiorenal risk reduction and continue to struggle with persistent albuminuria despite current standard of care treatment,” said George Bakris, MD, coauthor of the report and director of the Comprehensive Hypertension Center at the University of Chicago, in a statement. “It is compelling that we now have a general agreement between diabetologists and nephrologists on the use of Kerendia as part of a treatment plan for patients with CKD associated with T2D.”

“There has been a longstanding need in the CKD space for treatment options and multimodal approaches to patient care,” said Daniel J. Wilson, MD, FACP, FCCP, senior medical director of cardiovascular and renal, US Medical Affairs at Bayer. “… KERENDIA’s comprehensive clinical trial program, inclusive of patients comprising a range of disease severity and demonstrated evidence in providing cardiorenal risk reduction, has helped establish its place as an important piece of a comprehensive treatment paradigm for CKD associated with T2D.”

Full release -

[mr roper] 18/11/2022 14:51

Would agree with both.

The call on Wednesday, some good stuff mixed with the usual fluff and lack of targets. However, they’re now receiving payments from Medicare, Medicaid, blue cross blue shield and other private payers.

The VA has proved to be enormously bureaucratic and complex to implement KidneyIntelX into it. However progress is being made and they’ve refocused the VA Sales team to look at all sales channels.
Still pretty focussed on fda in Q1 and Medicare lcd most likely Q2. They admitted that the current Medicare method isn’t scalable enough to get them to the level they want so the lcd is required.
Expecting some new system announcements from Illinois.

All that said, I’d expect fda approval to be well received but the key is getting the test run rate up to 1000 a month ASAP for me.

[yasx] 18/11/2022 14:20

As a trading punt, and in anticipation of news, Renx seems a good bet for the short term. But, one has to remain fluid and not treat this as an investment.

[wan] 18/11/2022 11:45

Mr.R...Yes, it would indeed appear that there could well be some additional updates between now and the end of the year, but I also think the first quarter of next year could provide some pivotal news flow too.